Recombinant SARS-CoV-2 Spike S1 antibody (RBD)

Catalog No. ABIN6953041

The Human Monoclonal anti-SARS-CoV-2 Spike S1 antibody (Clone CR3022) (ABIN6953041) specifically detects SARS-CoV-2 Spike S1 in ELISA, Crys, SPR, Neut and IF. The antibody is reactive with SARS Coronavirus-2 (SARS-CoV-2) and SARS Coronavirus (SARS-CoV) samples.

Quick Overview for Recombinant SARS-CoV-2 Spike S1 antibody (RBD) (ABIN6953041)

Target: SARS-CoV-2 Spike S1

Antibody Type: Recombinant Antibody

Reactivity: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV)

Host: Human

Clonality: Monoclonal

Conjugate: This SARS-CoV-2 Spike S1 antibody is un-conjugated

Application: ELISA, Crystallization (Crys), Surface Plasmon Resonance (SPR), Neutralization (Neut), Immunofluorescence (IF)

Clone: CR3022

Product Details anti-SARS-CoV-2 Spike S1 Antibody

Binding Specificity: AA 318-510, RBD

Purpose: Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022], Human IgG1, Fc Silent™, kappa

Specificity:

This antibody binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" confromation of the spike protein (Joyce et al. 2020).

Application Notes original Clone: This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 < a href="https://www.medrxiv.org/content/10.1101/2020.03.17.20037713v1" target="_blank">(Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Bates et al. 2021 (PMID: 32766589) used CR3022 in a immunofluorescence assay.

Cross-Reactivity (Details): The anti-SARS-CoV-2 antibody CR3022 was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).

Purification: Protein A affinity purified

Immunogen: The original monoclonal antibody was generated through an scFv library derived from a peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

Isotype: Fc Silenced, IgG1, kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

OriginalSpeciesName: Human

OriginalFormat: IgG1

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for SARS-CoV-2 Spike S1

Target: SARS-CoV-2 Spike S1

Target Type: Viral Protein

Background: Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV, Ab1680.10, Ab1680.15, Ab1680.16

UniProt: P59594